Literature DB >> 30763031

Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing.

Steffen Dickopf1, Matthias E Lauer2, Philippe Ringler3, Christian Spick1, Peter Kern1, Ulrich Brinkmann1.   

Abstract

A novel bispecific antibody format was applied to generate T cell-engaging antibodies. The TriFab format is a trivalent IgG-shaped entity composed of two Fab arms that bind to antigens on the surface of tumor cells, which are linked via flexible peptides to a CD3 binding moiety that replaces the CH2 domains of conventional IgGs. The distinctive feature of these T cell recruiting bispecifics is that their CD3 variable regions are incorporated between domains, rather than N- or C-terminally fused to an Fc or antibody fragments. T cell recruiting TriFabs resemble in size and shape, are expressed and show biophysical properties similar to regular IgGs. Transmission electron microscopy (TEM) demonstrates high flexibility of the cell surface binding arms as well as target antigen accessibility of the interspersed CD3 binding domain. Functional co-culturing assays of peripheral blood mononuclear cells (PBMCs) and different tumor cell lines (MCF7 and A431) revealed a dose-dependent T cell-mediated cytotoxicity that was induced by the TriFabs targeting either LeY or EGFR cell surface antigens.

Entities:  

Keywords:  PBMC; T cell recruiting; TriFab; cytokine secretion; geometry; immunotherapy

Mesh:

Substances:

Year:  2019        PMID: 30763031     DOI: 10.1515/hsz-2018-0338

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  5 in total

1.  Bispecific antibodies: a novel approach for targeting prominent biomarkers.

Authors:  Akshita Gupta; Yatender Kumar
Journal:  Hum Vaccin Immunother       Date:  2020-07-02       Impact factor: 3.452

Review 2.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

Review 3.  Biology drives the discovery of bispecific antibodies as innovative therapeutics.

Authors:  Siwei Nie; Zhuozhi Wang; Maria Moscoso-Castro; Paul D'Souza; Can Lei; Jianqing Xu; Jijie Gu
Journal:  Antib Ther       Date:  2020-02-17

4.  Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies.

Authors:  Steffen Dickopf; Can Buldun; Vedran Vasic; Guy Georges; Carina Hage; Klaus Mayer; Matthias Forster; Uwe Wessels; Kay-Gunnar Stubenrauch; Jörg Benz; Andreas Ehler; Matthias E Lauer; Philippe Ringler; Sebastian Kobold; Stefan Endres; Christian Klein; Ulrich Brinkmann
Journal:  Biol Chem       Date:  2022-01-20       Impact factor: 4.700

Review 5.  Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies.

Authors:  Steffen Dickopf; Guy J Georges; Ulrich Brinkmann
Journal:  Comput Struct Biotechnol J       Date:  2020-05-14       Impact factor: 7.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.